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ABSTRACT
The tumor suppressor p53 is a sequence-specific
transcription factor, which regulates the expression
of target genes involved in different stress responses.
To understand p53’s essential transcriptional func-
tions, unbiased analysis of its DNA-binding repertoire
is pivotal. In a genome-wide tiling ChIP-on-chip
approach, we have identified and characterized
1546 binding sites of p53 upon Actinomycin D
treatment. Among those binding sites were known
as well as novel p53 target sites, which included
regulatory regions of potentially novel transcripts.
Using this collection of genome-wide binding sites, a
new high-confidence algorithm was developed,
p53scan, to identify the p53 consensus-binding
motif. Strikingly, this motif was present in the majority
of all bound sequences with 83% of all binding sites
containing the motif. In the surrounding sequences of
the binding sites, several motifs for potential regula-
tory cobinders were identified. Finally, we show that
the majority of the genome-wide p53 target sites can
also be bound by overexpressed p63 and p73 in vivo,
suggesting that they can possibly play an important
role at p53 binding sites. This emphasizes the
possible interplay of p53 and its family members in
the context of target gene binding. Our study greatly
expands the known, experimentally validated p53
binding site repertoire and serves as a valuable
knowledgebase for future research.
INTRODUCTION
The tumor suppressor gene p53 is the most frequently
mutated gene in human cancers (1). It can be activated by
a large number of stress signals. The p53 protein is able to
function as a sequence-speciﬁc transcription factor (2) and
it regulates the expression of target genes involved in
growth arrest, apoptosis, DNA repair, senescence, diﬀer-
entiation and other responses (3). Substantial evidence
indicates that the transcriptional functions of p53 are
necessary for p53-mediated tumor suppression (4),
although it has also been reported that p53 can induce
apoptosis without a functional transactivation domain (5).
The tumor suppressor p53 in a sequence-dependent
manner to a so-called p53 consensus-binding motif. This
motif is found in many identiﬁed binding sites of, mostly
upregulated, p53 target genes and consists of two copies of
the palindromic consensus half-site RRRCWWGYYY
separated by a spacer of 0–13bp, in which R¼purine,
W¼AorTandY¼pyrimidine(6).Thep53bindingability
and its transcriptional activity might be inﬂuenced by the
sequence of the two half-sites as well as their mutual
orientation (7,8). Up to now it was thought that this p53
response element is mostly found within a few thousand
base pairs of the transcriptional start site (TSS) (4). In
addition, binding sites which diﬀer from the classical p53
binding motif have been reported (9,10). It has been
suggested that the deviations from the consensus sequence
hint at the possibility that DNA topology also determines
p53 binding (11) and that even the DNA structure might
totally replace the consensus sequence (12). However, these
ﬁndings are largely based on single target genes; a genome-
wide analysis of binding sequences for common motifs will
be very informative.
The transcriptional activity of p53 can be regulated by
posttranslational modiﬁcations (13,14) as well as trans-
criptional cofactors and p53-binding proteins (4,15). p300
acts as an p53-dependent coactivator for p53 target genes
by acetylating p53 (16,17) and it binds to various core-
cruited factors that enhance the p53 response (18). Two
of those have recently been identiﬁed, JMY and Strap,
and both factors are required for p53 activity (19,20).
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selection of p53 target genes can be modulated by p53
interacting proteins. The ASPP (apoptosis-stimulating
protein of p53) proteins have been shown to interact
with p53 and to speciﬁcally modulate p53-induced apop-
tosis but not cell cycle arrest (21). Interestingly, the hCAS
(human cellular apoptosis susceptibility) protein has been
reported to be part of a distinct macromolecular complex
of p53at speciﬁc subsets of p53 target genes, e.g. Pig3 and
p53AIP1 and its knockdown attenuates the p53-dependent
apoptosis (22). Other transcription factors that might be
involved in the target gene selection of p53 are the Brn3
family of POU domain transcription factors (23), the YB1
protein (24), NF-kB and IKKa (25,26) as well as the
hematopoietic zinc-ﬁnger cofactor (HZF) protein (27). In
addition to transcriptional factors that inﬂuence the p53-
target gene binding, there is also evidence that the p53
family members p63 and p73 can contribute to the
p53-recruitment at speciﬁc target genes. Both p63 and
p73 were reported to be required for the p53 binding to the
p53 response elements of the target genes Perp, Bax and
Noxa, but not to those of p21 or Mdm2 (28). A ‘priming
model’ was suggested, in which p63 and p73 can bind to a
speciﬁc chromatin-embedded response element not acces-
sible for p53, and subsequently modify the context of the
responseelementinsuchawaythatitbecomesavailablefor
p53 binding (29). So far, a systematic analysis of the
capability of p63 and p73 to play a role in vivo at p53-target
sites has not been performed.
Many p53 target genes are currently known, e.g.
identiﬁed with microarray expression proﬁling (30,31),
and at the moment it is intensively studied how p53
determines which target genes to activate or repress in a
certain stress response (4,32). In addition to the experi-
mentally identiﬁed p53 target genes, there are also
computationally predicted binding sites (33,34). These
predictions do not necessarily reﬂect the actual target
sites bound in vivo by p53. For the selection of functional
binding sites, the involvement of other cellular factors,
chromatin accessibility, DNA sequences surrounding the
potential binding site and DNA topology have to be taken
into consideration, in addition to the consensus-binding
sequence itself. These factors can not yet be accurately
modeled. It is estimated that there are between 300 and
3000 binding sites for p53 in the human genome, based on
studies from Hoh et al. (34), ChIP-on-chip (chromatin
immunoprecipitated DNA hybridized on DNA arrays)
data extrapolated from chromosome 21–22 (35) and ChIP-
on-chip data derived from ENCODE regions (36). Since
there are only about 180 experimentally conﬁrmed target
genes (30), and 542 high-probability binding sites (37), it is
expected that there are still many unidentiﬁed binding sites
and target genes, notwithstanding several studies that have
reported binding sites for p53 (35–42). Furthermore, it
remains to be seen how a comprehensive set of p53-DNA
bindingsitesinvivocanbeusedtogivemoreinsightintothe
diﬀerent transcriptional functions of p53.
Here, we report a genome-wide ChIP-on-chip study of
p53 employing high-resolution tiling arrays with an
average probe spacing of 100bp. We have identiﬁed 1546
high-conﬁdence sites and performed extensive analysis of
the in vivo binding sites with respect to their sequence as
well as surroundings and nearby genes. We report the
development of a new publicly available algorithm,
p53scan, to identify the p53 consensus binding motif with
high speciﬁcity. The motif is present in 83% of all the p53-
bound sequences and in almost all highly enriched binding
sites. Potential novel functions of p53 derived from the
global binding sites were investigated and validated. To
obtain a more complete picture of the in vivo bound target
genes of p53, we have also performed ChIP-on-chip ana-
lyseswithtwoofitsfamilymembers,p63andp73.Weshow
that a large fraction of these newly identiﬁed binding sites
for p53 could also be bound by p63 and p73 in vivo.
MATERIALS AND METHODS
Cell cultureand drugtreatment
The human osteosarcoma cell lines U2OS expressing
endogenous wild-type p53, and Saos-2, which are p53
null (43), were maintained in Dulbecco’s modiﬁed Eagle
medium supplemented with 10% fetal calf serum at 378C.
The Tet-on inducible expression system (BD Biosciences,
Breda, The Netherlands) was used in Saos-2 cells to
generate cell lines that conditionally express FLp53,
TAp63a or TAp73a. cDNA of the gene of interest was
cloned into the pTRE vector and cotransfected with the
pZoneXN, which has a puromycin selection marker, into
Saos-2 cells. Transfections were performed by the calcium
phosphate precipitation method. Stable clones were
selected with 1mg/ml puromycin (Sigma, Zwijndrecht,
The Netherlands). To induce the expression of FLp53,
TAp63a or TAp73a,2 mg/ml doxycyclin (Sigma), a
Tetracyclin homologue, was added to the medium. The
inducible Saos-2 cell lines were ﬁrst induced with doxycy-
clin for 24h and then treated with 5nM Actinomycin D
(Sigma) for another 24h. The U2OS cells were treated with
5 nM Actinomycin D for 24h.
Cell cycle analysis
Cells were induced and treated as described above. The
cells were ﬁxed with 96% ethanol and stained with pro-
pidium iodide (Sigma). DNA content was analyzed by
ﬂow cytometry (Becton Dickinson FACScan) and ana-
lyzed using CellQuest Pro software.
Immunoblotting
To assess protein levels, proteins from whole-cell extracts
were harvested, lyzed and separated by SDS–PAGE and
analyzed by western blotting with a-p53 (DO1, BD
PharMingen, Breda, The Netherlands).
Transactivation assays
The selected binding sites were ampliﬁed from genomic
U2OS DNA and cloned behind the luciferase gene into the
pGL3-promoter vector (Invitrogen, Breda, The
Netherlands), which contains a luciferase reporter gene
behind a SV40 promoter. U2OS cells were transiently
transfected with pGL3 constructs and a pRL-TK reporter
(Promega, Leiden, The Netherlands), constitutively
3640 Nucleic Acids Research, 2008, Vol. 36, No. 11expressing Renilla as a normalization control, by calcium
phosphate transfection. Cells were lyzed and luciferase
activity was measured using the Dual-Luciferase Reporter
Assay System (Promega).
RNA isolation and RT–PCR
Total RNA was extracted using the RNeasy Mini kit
according to protocol (Qiagen, Venlo, The Netherlands).
For cDNA synthesis, reverse transcription was performed
with 1mg of the total RNA, oligodT anchor primers,
dNTPS, DTT, buﬀer and Superscript Retrotranscriptase
(Invitrogen). cDNA was analyzed by qPCR using a MyIQ
machine (Biorad, Veenendaal, The Netherlands). Primers
used for real-time PCR are available upon request.
ChIP and ChIP-on-chip
Chromatin immunoprecipitation (ChIP) was essentially
performed as described by Denissov et al. (44). The cells
were sonicated using a Bioruptor sonicator (Diagenode,
Liege, Belgium) for 15min at high power, 30s ON, 30s
OFF. Antibody incubation with chromatin from U2OS
cells treated with Actinomycin D was performed overnight
at 48C with 2mg of DO1 antibody (BD PharMingen). For
ChIP experiments in Saos-2 inducible cell lines DO1 (BD
PharMingen), 4A4 (Abcam, Cambridge, UK) and BL906
(Abcam) were used for p53, p63 and p73, respectively.
Real-time PCR was performed using the SYBR Green mix
(Biorad) with the MyIQ machine (Biorad). Primers used
for real-time PCR are available upon request. To produce
more material for a ChIP-on-chip, the total DNA and
ChIP DNA needed to be ampliﬁed. For genome-wide
hybridization, the material was ampliﬁed using LM-PCR
ampliﬁcation (45). The T7-based ampliﬁcation procedure
(46) was used for the hybridizations on the dedicated
arrays. The total DNA and ChIP DNA were hybridized to
whole genome tiling arrays (HG17Tiling Set) or custom
designed microarrays manufactured by NimbleGen
Systems, Inc., Madison, WI, USA. Raw data for all
microarray hybridizations are available at ArrayExpress
(http://www.ebi.ac.uk/arrayexpress) under accession
E-TABM-442.
Custom microarray design
Peak detection (see below) was performed on the genome-
wide dataset and all probes within the positive regions
recognized by the peak detection procedure, extended
equally up- and down-stream to a total of 2kb, were
spotted on a custom design array (NimbleGen Systems),
hereafter referred to as dedicated design. All the probes
from a continuous region of chromosome 21 (from 28 692
406 to 41 270 931) on the hg17 array were included in the
dedicated design to provide a baseline for normalization
purposes. This region is hereafter referred to as tilepath.
Data normalization
The probe sequences from both the whole genome and the
dedicated design were compared to the human genomic
sequence with BLAT (47). Probes with 10 or more
matches were discarded for use in the subsequent analysis.
The raw probe ratios were normalized within arrays using
Tukey’s biweight. For all hybridizations performed on the
dedicated array, the ratios were normalized against the
tilepath region.
Peak detection
The microarray data were analyzed using three diﬀerent
peak detection programs to identify putative targets with a
high degree of conﬁdence. Default parameters were used
except where noted. The proprietary program provided by
NimbleGen was run with a 1% false positive rate. For
Tilemap (48), hybridization length was set to 50 and
maximal gap size to 100. All probes with posterior
probability of at least 0.9 were deﬁned as peaks. For
Mpeak (49), the maximum gap was set to 300, and a
minimum log2 ChIP/Total ratio of at least 2.5 SD was used
as a threshold. All positive regions or peaks <1kb in length
were extended equally up- and down-stream to cover 1kb.
Perbiologicalreplicateallregionsdeterminedtobepositive
byone of the programs were combined. Finally, apeak was
deﬁned as a binding target if positive regions shared any
overlap in each biological replicate.
Mapping bindingsites to genes
Target locations were mapped to NCBI 36 coordinates
using the Batch Coordinate Conversion (liftOver) utility
provided by the UCSC Genome Bioinformatics group.
Gene locations of all genes were downloaded from Ense-
mbl [release 43, February 2007 (50)]. To map a target to a
gene, the distance from the middle of the target to the
Ensembl gene start was used.
Annotation of genes
For annotation of genes, only target genes with a binding
site within 5kb of the gene were used. Overrepresented
Gene Ontology (GO) (51) categories within annotation of
the target genes were determined with Ontologizer using
the parent–child method, which takes into account the
parent–child relationships of the GO hierarchy (52). The
P-values were adjusted using Westfall–Young single-step
multiple testing correction and a corrected P-value
threshold of 0.05 was used as a cut-oﬀ for reporting
signiﬁcant matches. Genes were annotated with KEGG
pathways (53) using Fatigo+ (54). Overrepresented
pathways were determined according to the hypergeo-
metric distribution with a P-value threshold of 0.05.
The p53scan algorithm and motif analysis
Sequences of equal length were selected for all targets by
determining the probe with the highest mean ratio value
within each peak and selecting a 500bp region centered on
this probe. All probes within regions on the slide of at
least 10 consecutive probes, or 1kb, with a maximum
mean log2 ChIP/Total ratio of 0.5 were selected as
background sequences. These sequences were divided in
500bp regions to create sequences of the same length as
the target sequences.
To determine the optimal positional weight matrix
(PWM) for p53scan, the de novo motif discovery program
Nucleic Acids Research, 2008, Vol. 36, No. 11 3641MDmodule (55) was applied to half of the 500bp target
sequences, 773 in total. Sequences were ordered based
on the ChIP/Total ratio of the highest probe in the
peak. MDmodule was run with a width of 20 and the
number of top sequences to look for motifs was set to 200.
Default parameters were used for all other options. The
MDmoduleoutputwas subsequently convertedto aPWM.
In p53scan, the score of a subsequence   of length L is
calculated as follows:
X L
i¼1
ln
fi,b
g
þ z
  
where fi,b is the fraction of each nucleotide at position i, g
is 0.25 and z is 0.01.
To incorporate a variable spacer length, the two half-
sites are scanned separately and the scores for each half-
site are combined. Cutoﬀs for spacer lengths greater
than 0 were determined by scanning 10 times as many
random nonbound sequences and choosing the threshold
that result in no hits. This enables p53scan to take high-
scoring motifs with spacer lengths other than 0 into
account without drastically changing the false positive
rate (FPR).
To test the performance of the algorithm and to com-
pare it to other available algorithms, the 773 sequences
not used for training were compared to a background set
of ﬁve times as many random nonbound sequences. Three
diﬀerent metrics were used for comparison:
(1) The area under the receiver operator curve (ROC
AUC), which reﬂects the balance between the false
positive rate and the true positive rate.
(2) The mean normalized conditional probability
(MNCP) as described by Clarke and Granek (56).
(3) The maximum F-measure or weighted harmonic
mean of precision and recall.
Recall ¼
TruePositives
TruePositives þ FalseNegatives
Precision ¼
TruePositives
TruePositives þ FalsePositives
F   measure ¼
2   Precision   Recall
Precision þ Recall
The process of randomly selecting training, test and
background sequences and subsequent performance com-
parison was repeated in 10 independent runs. In all cases
the performance was comparable. The best scoring PWM
was kept and implemented. All 1546 targets were com-
pared to ﬁve times as many randomly selected noncoding
sequences of equal length to produce Figure 4B.
Subsequently, p53scan was used to analyze the complete
set of target sequences with a score cutoﬀ of 4.393 for
spacer length 0 resulting in the highest F-measure,
corresponding to an estimated FPR of  7%.
For de novo motif prediction of possible cofactor motifs,
themotifdiscoveryprogramMDmodulewasappliedtothe
500bp target sequences. The same procedure as described
for the p53scan PWM was followed. The number of top
sequences to look for motifs was set to 100, all widths from
6 to 16 were considered, and the number of motifs to report
was setto 10.Tocalculate thesigniﬁcance ofthe discovered
motifs, the number of sequences with at least one motif
instance with 0.8 maximum possible score was deter-
mined in both the sample and the background sequences
using TAMO (Tools for Analysis of Motifs) (57). For each
motif a P-value was calculated using the hypergeometric
distribution. The corresponding signiﬁcance value was
calculated as Signiﬁcance ðSÞ¼ log10ðP valueÞ.
As selection criteria, we used a signiﬁcance cut-oﬀ of 1.3
corresponding to a P-value of 0.05 with a minimum of
occurrence of at least 10 times. All signiﬁcantly enriched
motifs were clustered using a k-medoids clustering algo-
rithm as described in (58). Clustered and aligned motifs
were averaged to produce consensus motifs. The signiﬁ-
cance of the resulting motifs was determined as described
in the previous paragraph.
To analyze target sequences for known motifs, the
sequences were scanned with all the position weight
matrices from the TRANSFAC database (public release
version 6.0) (59) and further analyzed as described in the
previous de novo motif prediction section. Similar motifs
were grouped and averaged.
RESULTS
Genome-wide identification of p53-binding sites
using ChIP-on-chip
In order to detect in vivo binding sites for p53 on a genome-
wide scale, we applied the ChIP-on-chip approach to
endogenous p53 expressing U2OS osteosarcoma cells. In
unstressed cells, endogenous p53 is maintained at low
levels. To activate p53, cells were treated with 5 nM Acti-
nomycin D for 24h (60). Upon Actinomycin D treatment,
p53 is stabilized and growth arrest is induced (Figure 1A
andB).ChIPwasperformeduponthistreatment.Toassess
the speciﬁcity of our ChIP-results, p53 binding to exon 2 of
the myoglobin gene was determined as background signal
and enrichment was calculated as fold binding over
background signal (Figure 1C). For the p21-promoter, an
enrichment of p53 binding of almost 600-fold was attained
showing that the immunoprecipitation was highly speciﬁc.
For the global binding site analysis, the enriched (ChIP)
sample and the nonenriched (Total) DNA sample were
ampliﬁed, diﬀerentially labeled and cohybridized to 38
DNA arrays covering the whole human genome (repeat
masked) with a probe spacing of 100bp and a probe length
of 50bp (NimbleGen Systems, Inc.).
We called putative p53-binding sites combining three
diﬀerent peak extraction algorithms to maximize the
number of potential peaks. The genomic loci of the
combined peaks were combined to generate a so-called
dedicated array (61), which was used to hybridize two
further biological replicate experiments (Figure 1D). If a
peak was identiﬁed in all three biological replicates, it was
considered as a high-conﬁdence p53-binding site. This
way, we identiﬁed in total 1546 high-conﬁdence binding
sites for p53. Veriﬁcation of the identiﬁed binding sites
3642 Nucleic Acids Research, 2008, Vol. 36, No. 11was performed by quantitative PCR with three indepen-
dent ChIP experiments. In total, 50 potential binding sites
were randomly selected and tested. This resulted in a
conﬁrmation of 48 out of 50 sites. We conclude that we
identiﬁed 1546 genome-wide p53-binding sites with a false
positive rate of  4%.
Since several studies, using diﬀerent ChIP-based tech-
niques, have identiﬁed binding sites for p53 in various
cell systems (35–38,62), we compared these to the
collection of our binding sites (Table 1). The overlap
between our data set and the PET5 cluster in the
ChIP-PET data set for p53 by Wei et al. (37) was 69%,
even though diﬀerent cell lines and treatments were used
(Figure 1E). The extensive overlap with the highest ranked
targets of the ChIP-PET data (69%) and lower overlap
(17%) in the low ranked targets with ChIP-PET data is in
concordance with the study of Euskirchen et al. (63),
where they compared ChIP-sequencing with ChIP-on-chip
under the same conditions for STAT1 and also found the
most overlap in the highest ranked regions. From the
genes that were identiﬁed by a ChIP-based screen in yeast
(41), 50% are found in our study. Thus, even when using
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Figure 1. Genome-wide identiﬁcation of p53-binding sites using ChIP-on-chip. (A) Representative cell cycle proﬁle of U2OS cells untreated or treated
for 24h with 5nM Actinomycin D. (B) Western blot showing p53 expression levels of U2OS cells, untreated or treated for 24h with 5nM
Actinomycin D. (C) ChIP enrichment (fold over negative control, myoglobin) of p53at the p21 promoter and the intronic binding site of GADD45A.
(D) ChIP-on-chip proﬁle of p53 binding to chromosome 6 visualized using Signalmap (NimbleGen Inc.). Shown are the log2 ratio of ChIP/Total
signal derived from the genome-wide tiling data and a zoomed-in view of binding to the p21 promoter for all three biological replicates. Genes are
represented by thick horizontal bars (plus-strand positive, minus-strand negative). (E) Overlap of the ChIP-on-chip derived p53-binding sites with
PET5+ data from Wei et al.
Nucleic Acids Research, 2008, Vol. 36, No. 11 3643diﬀerent cellular systems and physiological conditions as
well as various ChIP-based techniques, half or more of the
p53-binding sites appear to be overlapping with our global
ChIP-on-chip approach, showing we created a high-
conﬁdence p53-binding dataset.
Characterization ofidentified p53-binding sites
To annotate the identiﬁed p53 binding sites, their locations
were analyzed with respect to annotated Ensembl genes.
We found that 21% of all p53-binding sites mapped to TSS
ﬂanking regions (5kb upstream, ﬁrst exon and intron),
28% were within a gene (excluding ﬁrst exon and intron),
3%within 5kbdownstream, 16%within 5–25kbupstream
or downstream and 32% in intergenic regions (Figure 2A).
We compared the frequency of p53 binding in speciﬁc
genomic regions to the distribution of these genomic
regions over the whole genome (using Ensembl gene
annotations) and found that p53-binding sites are sig-
niﬁcantly enriched in TSS ﬂanking regions and within
5–25kb upstream or downstream of a gene (P¼1.49E-009
and 0.0094, respectively) (Figure 2A).
To study if binding of p53 in TSS ﬂanking regions can
regulate the transcription of the corresponding gene
products, we randomly selected 11 genes in this group to
test their changes of expression upon p53 activation
(Figure 2B). Four of these genes were indeed more than
2-fold upregulated, two were >2-fold downregulated, and
ﬁve did not change >2-fold. Thus, upon p53 binding in
TSS ﬂanking regions, genes can get activated or repressed
by p53, which is in accordance with the described function
of p53 as transcriptional activator and repressor.
While the biological function of p53 binding to
promoter regions is well established, we wanted to study
the functional potential of intronic as well as intergenic
p53 binding. We ﬁrst tested nine of the intronic and
intergenic binding sites (randomly chosen) in transactiva-
tion assays cloning them into a pGL3-promoter-luciferase
vector, which can be used to test enhancer functions.
U2OS cells were transiently transfected with these
luciferase constructs and treated with Actinomycin D to
activate p53. For each of the selected binding sites, the
luciferase activity increased two to nine times compared to
the pGL3prom control vector (Figure 2C). This indicates
that p53-binding sites in introns and intergenic regions can
play a role as transcriptional enhancers.
To test whether the p53 binding in intergenic regions
could also regulate the transcription of novel gene
products, we mapped the intergenic binding sites to
human expressed sequence tags (ESTs). This revealed
that 67% of intergenic p53-binding sites are located within
5kb up- or down-stream of an EST. This is a signiﬁcant
enrichment (P¼1.50E-4) compared to the proportion of
the complete genome that falls within this category. From
these binding sites close to an EST, we chose four sites for
further analysis (Figure 2D, upper panel). We validated
binding of p53 to these sites in targeted ChIP experiments
(Figure 2D, lower left panel) and tested changes of
expression of these novel transcripts upon p53 activation.
The four chosen transcripts showed a 2- to 15-fold
induction (Figure 2D, lower right panel) upon p53
activation. This indicates that many novel, currently
unannotated transcripts may be regulated by p53.
Functional annotation of thep53-binding sites
Since we found well-known p53 target genes involved in
pathways such as DNA repair (GADD45A, DDB2), cell
cycle regulation (MDM2, p21) and apoptosis (BAX, DR5)
(Table S1), we wanted to analyze the possible biological
roles of all the p53-binding sites in our dataset. When we
grouped our p53 targets, which have a binding site within
5kb, according to function in GO using Ontologizer
(52,64), we found several new groups of target genes that
have not been linked to p53 function before or that expand
p53’s functions such as the phosphorus and biopolymer
metabolism group(Figure 3A). Metabolic changesoccur in
many cancers and recently p53 has been linked to changes
in metabolism (65). The fact that we ﬁnd metabolism-
related genes signiﬁcantly enriched in our binding site list
could well indicate that p53 plays an even wider role in
metabolic changes besides the so far described function of
p53 in glucose metabolism and oxidative stress (66).
To study the involvement of our identiﬁed p53-target
genes in entire biological pathways, we classiﬁed them
according to the Kyoto Encyclopaedia of Genes and
Genomes (KEGG) using FatiGO+ (54). Axon guidance
and calcium-signaling pathways (Figure 3B) are signiﬁ-
cantly overrepresented in our dataset, suggesting a hitherto
undescribed role for p53 in these biological processes. To
study the axon guidance target gene group further, we
randomly chose three genes from this group for our
analysis: SEMA3C, SEMA6A and SEMA3A (Figure 3C,
upper panel). We validated the ChIP-on-chip data
(Figure 3C, upper panel) by targeted ChIP and found a
signiﬁcant enrichment of p53 binding upon Actinomycin D
treatment of U2OS cells to all tested sites (Figure 3C, lower
panel). Thus, it remains to be elucidated which role the
target genes from the axon guidance group could play
during the p53-mediated stress response.
Table 1. Overlap with published data sets
Published study Total number
of binding sites
Overlap with p53
of this study
(1546 total)
Yang et al. (62) 5807 383
Wei et al. (37) PET2+ 1773 301
PET2+
with
p53PET
motif
542 262
PET3+ 327 170
PET4+ 169 111
PET5+ 106 73
Krieg et al. (38) Low 113 3
Mid 34 1
High 8 1
Cawley et al. (35) 48 15
Kaneshiro et al. (36) 37 16
Hearnes et al. (41) 38 26
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Figure 2. Characterization of identiﬁed p53 binding sites. (A) Distribution of the p53-binding site location relative to Ensembl genes (upper panel)
compared to the genome-wide distribution (lower panel). Locations of binding sites are divided in TSS ﬂanking region (5kb upstream of TSS+ﬁrst
exon+ﬁrst intron), intragenic region (all introns and exons except ﬁrst), 5kb downstream (5kb downstream of last exon), 5–25kb up- or down-
stream or intergenic regions (everything else). The asterisk represents signiﬁcant enrichment. (B) Expression change of genes which have a p53
binding site in the TSS ﬂanking region. The expression change is shown after 24h of 5nM Actinomycin D treatment in fold over untreated U2OS
cells. Error bars represent standard deviation of three independent experiments. (C) Transactivation assay of intronic (yellow) and intergenic (blue)
p53-binding sites. The relative luciferase activity is plotted in fold over empty vector. Error bars represent standard deviations of three independent
biological replicates. (D) Binding proﬁle and expression change of four ESTs bound by p53. In the upper panel, the ChIP-on-chip data is visualized.
In the lower left panel, these binding sites are conﬁrmed by targeted ChIP for p53. Shown is the enrichment in fold over negative control
(myoglobin). In the lower right panel, the expression change of the EST is shown after 24h of 5nM Actinomycin D treatment in fold over untreated
U2OS cells. Error bars represent standard deviation of three independent experiments.
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finding algorithm
The p53 DNA binding site has been characterized and is
consistently described as two copies of the half-site RRR
CWWGYYY separated by a spacer of 0–13bp,
where R¼purine, W¼A or T and Y¼pyrimidine.
Although this may be the most optimal sequence for p53
binding, only 52 out of the 1546 binding targets in this
study contain a perfect match to this sequence. Thus, the
p53 motif shows a high degree of degeneracy, which could
create the versatility of diﬀerent p53-mediated stress
responses in vivo. Diﬀerent approaches for identifying
the degenerate p53-consensus binding motif have been
described. Most are based on a PWM scoring method
although recently an algorithm based on experimentally
measured binding aﬃnity was shown to give interesting
results (33).
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preference of a transcription factor is a crucial parameter
for identifying binding sites with PWM algorithms. The
diﬀerent PWMs that have been described for p53 until now
were constructed based on only 17 (TRANSFAC) to 39
(37) binding sequences. Consequently, these PWMs only
reﬂect the information present in those few sequences.
Therefore, not surprisingly, using p53MH (which uses a
PWM based on 37 sequences) with a cutoﬀ of 90 as
suggested by the authors (34), we ﬁnd that only 33% of our
high-conﬁdence binding sequences contain amotif. Having
identiﬁed a set of genome-wide binding sites, we wondered
if we could use the information encompassed in a wide
variety of p53-binding sites to develop a more sensitive
algorithm. We randomly selected 773 sequences (one half
of our identiﬁed binding targets) and ordered these based
on the ChIP/Total ratio of the highest probe in the peak.
We used the de novo motif prediction program MDmodule
(55) on the ordered sequences to predict the p53 motif
(Figure 4A). The PWM was constructed from these results
(matrix shown in Table S2) and combined with a
scoring scheme adapted from the p53MH model. This
approach enabled us to greatly increase the amount of
binding sequences with an identiﬁed p53 motif up to 83%
(FPR  7%).
The performance of our algorithm, p53scan, was
benchmarked on the binding sites identiﬁed in this study
(the ones not used for training) and the human p53-
binding sites identiﬁed previously by ChIP in combination
with paired end tag sequencing [ChIP-PET 3+ (37)]. We
compared the performance to p53MH and to the Match
algorithm (67) with the p53 PWM from TRANSFAC,
using three diﬀerent metrics: ROC AUC, MNCP (56) and
the harmonic mean of precision and recall (F-measure).
The training and benchmarking process was repeated in
ten independent runs and the average results are shown
in Table 2. We implemented the best performing PWM in
p53scan, and compared the performance on all binding
targets to p53MH and Match (Figure 4B). We also
compared p53scan to the ChIP-PET algorithm described
by Wei et al. (37) using the ChIP-PET 3+ sequences. The
authors identiﬁed 72% of these sequences as having a
motif using p53PET with an estimated FPR of 0.68%.
Using p53scan on their sequence set with the same
estimated FPR, we ﬁnd a p53-binding motif in 82% of
the binding sites. These results clearly show that p53scan
can identify more p53 motifs in the evaluated sequence
sets than the currently described algorithms, without
lowering speciﬁcity.
The possibility of a spacer within the p53 motif deserves
special consideration. If all spacer lengths from 1 to 13 are
considered without specifying additional constraints the
false positive rate of a PWM algorithm like p53scan greatly
increases, due to the greater number of possible motifs
that is evaluated. As can be seen in Figure 4C most of our
p53-binding motifs actually do not have a spacer between
the two half sites. Therefore by default p53scan employs a
strict score threshold for all spacer lengths other than 0.
The score threshold for each individual spacer length was
selected by scanning a background sequence set (random
nonboundsequencesofequallength)foreachspacerlength
and selecting the cutoﬀ that resulted in no hits. Thus, we
have developed a highly speciﬁc and inclusive algorithm to
identify p53-binding motifs, which is freely available at:
http://www.ncmls.nl/bioinfo/p53scan.
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Figure 4. Development of p53scan, a p53-motif ﬁnding algorithm.
(A) p53 motif identiﬁed de novo with MD-module, visualized using
WebLogo. (B) ROC curve comparing p53scan, p53MH and Match.
The FPR used to characterize the p53-binding sites ( 7%) is marked.
(C) Distribution of spacer length in the p53 consensus sites based on
the p53scan algorithm.
Table 2. The performance of p53scan
p53 ChIP-on-chip p53 ChIP-PET 3+
MNCP AUC F-measure MNCP AUC F-measure
p53scan 8.67 0.90 0.86 3.97 0.93 0.91
p53MH 5.62 0.83 0.76 3.37 0.86 0.81
Match 7.35 0.82 0.82 3.49 0.87 0.81
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The p53scan cutoﬀ resulting in the highest F-measure
(FPR  7%, as marked in Figure 4B) represents a balance
between retrieving false positives and missing false nega-
tives. We have used this setting to analyze and further
characterize the bound target sites identiﬁed in this
study. We found the p53 motif in 1281 out of 1546
(83%) binding sites. We determined the location of the
consensus motif with respect to the ChIP-on-chip data
and found it to be located mainly in the centre of the peaks
(Figure 5A). To study whether there is a correlation
between the ChIP/Total binding ratio of p53 and the
occurrence of the p53-binding motif, we ranked the
identiﬁed p53-binding sites according to their relative
binding enrichment (log2 ChIP/Total) and divided them
into three subgroups of low, medium and high ratios. The
percentage of binding sites, which contain the p53-binding
motif increased slightly with the binding ratio of the
peaks. In the high-enrichment subgroup (468 sites with a
log2 ChIP/Total ratio of at least 3.17), almost 90% of the
p53-binding sites contain a p53-binding motif (Figure 5B).
Next, we analyzed the binding enrichment as measured
by ChIP/Total signal ratio in relation to the exact com-
position of the consensus site. We averaged the binding
ratio as a function of the number of mismatches to the
consensus motif (Figure 5C). This shows that there is a
correlation between enrichment in vivo as measured by
ChIP-on-chip and the nucleotide composition of the p53-
binding motif.
Since 52 ( 11%) of the sequences in the high subgroup,
consisting of the most highly enriched targets (Figure 5B),
do not contain a p53-binding motif as identiﬁed by
p53scan, we tried to further characterize the motifs in
these sequences. When we expand the peak area to 1.5kb,
p53scan can ﬁnd a binding motif in 43 out of the 52
sequences, using settings that result in only 15 motifs
found in 1500 random coding sequences of equal length
(FPR  1%). In these cases, the actual calling of the peak
area could have been imprecise, most likely due to the
binding site being located in repeat-masked areas.
Remarkably, when we take these matches into account,
in total 98% of the sequences in the high subgroup contain
a p53 motif.
Transcription factorbinding motifs inthe vicinity
of theidentified p53-bindingsites
Corecruited DNA-binding factors (18) have been invoked
to play a role in the ﬂexible response of p53 to various
stress signals. We therefore analyzed the vicinity of the p53
sites (500bp centered on the peak of the p53 binding) for
the potential presence of other known transcription factor
binding sites, using TAMO (57) with the TRANSFAC
database (59). Predicted binding sites of eight diﬀerent
motifs of transcription factors were found to be signiﬁ-
cantly overrepresented in the surrounding sequences of the
p53-binding sites (Figure 6). Among those were potential
binding sites for Kru ¨ ppel-like factors (KLF), Sp1/Sp3, the
group of basic helix–loop–helix (bHLH) proteins, AP1,
AP2, MZF1, CP2 and ETS2. Many of these factors that
we have found to be statistically enriched in our genome-
wide collection of p53-binding sites have been experimen-
tally shown to inﬂuence p53-dependent transcriptional
activity for single target genes. The most overrepresented
motif in our dataset are the motifs for KLF; it has been
suggested that KLF 4 is a mediator of p53 in controlling
progression of the cell cycle following DNA damage (68).
Interestingly, p53 has been reported to require
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Figure 5. Characterization of the p53-binding motif. (A) Histogram of
the distance of the p53 consensus site to the probe with the highest
mean ratio within a binding site, based on the p53scan algorithm.
(B) Percentage of binding sites containing a motif relative to binding
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3648 Nucleic Acids Research, 2008, Vol. 36, No. 11cooperation of Sp1 or a Sp1-like factor for the transcrip-
tional activation of the human BAX promoter (69) as well
as for p21 (70). To ﬁnd out if the potentially cobinding
transcription factors might inﬂuence p53-transcriptional
activity towards a speciﬁc direction of the response
pathway, we looked at the diﬀerent subsets of the p53-
binding sites containing a speciﬁc motif. We analyzed the
potential biological signiﬁcance of the genes, which are
within 5kb of these binding sites using GO annotations, as
described above. Three signiﬁcantly enriched GO cate-
gories were found for the cobinding factors: develop-
mental, metabolic and cell–cell signaling pathways
(Table 3). In all three pathways p53 has been reported
to play a role. Our data thus supports the notion that the
response pathways of p53 might be inﬂuenced by the
identiﬁed potential cobinding transcription factors.
p63 and p73binding to p53targets
The p53 family members p63 and p73 have been reported
to contribute to the p53 stress response in certain tissues
in vivo (28,71). They might play a role in the regulation of
transcriptional activities of p53 as well as potential
cobinding transcription factors as evidenced by their
inﬂuence on p53’s ability to bind to various apoptotic
promoters in vivo (28,71). Furthermore, Yang et al. (62)
studied the genome wide binding of p63 and identiﬁed a
p63-speciﬁc motif. Since this motif strongly resembles the
motif to which p53 binds, we were interested if and to
what extend p63, and the other p53 family member p73,
can bind to our identiﬁed p53 global binding sites. Because
of possible cell-type speciﬁc diﬀerences in the transcrip-
tional response pathways of the p53-family, a cellular
system was needed that would allow a direct comparison
between p53, p73 and p63. We generated Saos-2 cell lines
expressing TAp63a, TAp73a or p53 under a tetracycline-
inducible promoter. We performed ChIP-on-chip analysis
for p63 and p73 as well as overexpressed p53 on the
dedicated array. Comparing the binding sites identiﬁed for
endogenous p53 in U2OS cells to those identiﬁed for
exogenous p53 in the Saos-2 p53 cell line, we found that
1112 of the endogenous binding sites (72%) are bound by
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Figure 6. Overrepresented transcription factor binding motifs in the vicinity of identiﬁed p53-binding sites. Known transcription factors motifs
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Nucleic Acids Research, 2008, Vol. 36, No. 11 3649exogenous p53 as well. Very interestingly, if we compare
these1112p53exogenous-bindingsites,whichoverlapwith
the binding sites occupied by wt endogenous p53, 72% of
those p53-binding sites could also be bound by p73 and/or
p63 in vivo (Figure 7). With the majority of the p53-binding
sites also being bound by p73 and p63, there seems to be
good evidence that p63 and p73 could play an important
role in the p53 transcriptional response pathways.
To investigate whether binding sites that can be bound
only by p53 or also by p73 and p63 show sequence
diﬀerences,wecomparedthep53motifbasedonp53scanin
shared binding sites (Figure 7B, upper panel) and binding
sites which are not bound by p63 and p73 (Figure 7B lower
panel). These motifs very much resemble each other,
independently of whether they are bound by p53 only or
by all three family members. Accordingly, p63 and p73 are
actually able to bind sequences containing this p53-binding
motif on a global scale. The p53-binding motif was
identiﬁed in 86% of the shared binding sites and in 76%
of the binding sites for p53 only. It remains to be elucidated
which other parameters of a p53-binding site determine
whether it can be bound by p53 only or also by the family
members. It has been shown in vitro that ﬁve speciﬁc bases
in the p53 consensus sequence are important for stable
binding of p73 to DNA (72). These speciﬁc nucleotides are
present in 9.6% of the motifs found by p53scan in the
sharedbinding sites, andin10.8% ofthemotifs inp53-only
binding sites. Therefore, according to our observations this
speciﬁc characteristic of the p53 consensus motif cannot
explain the diﬀerence between p53 only and shared binding
site of our genome-wide in vivo binding data.
Besides diﬀerences in the p53 motif, we also analyzed
the p53 only versus the shared binding sites in respect to
their genomic location, GO annotation, and the potential
presence of other known transcription factor binding sites,
as described above, but could not observe signiﬁcant
diﬀerences (data not shown). Thus, we found that the
DNA binding characteristics of the p53-binding sites
which were bound by its family members closely resemble
those that were bound by p53 only.
DISCUSSION
Genome-wide identification ofp53-binding sites
To characterize the transcriptional mechanisms of the
p53-mediated stress response, we analyzed p53 binding to
chromatin on a genome-wide scale using the ChIP-on-chip
approachandidentiﬁed1546high-conﬁdencebindingsites.
While these binding sites were signiﬁcantly enriched in
TSS ﬂanking regions, encompassing possible promoters,
a large fraction was located in intragenic or intergenic
regions, as also observed in other studies (37,41). We and
others have provided evidence for functionality of these
intergenic binding sites. In our reporter assays, we could
show that the intergenic and intragenic p53-binding sites
can function as enhancers. Likely, the interaction between
enhancer and target gene is mediated via loop formation,
as shown for example for the Hoxd gene cluster and the
b-globin locus (73). Furthermore, the intergenic-binding
sites could be involved in regulation of nonprotein coding
genes as well as other novel transcripts, as has been
suggested by smaller scale ChIP-on-chip analyses (35).
In our study, we discovered that unannotated transcripts
located near intergenic p53-binding sites can be upregu-
lated upon p53 activation.
Table 3. Enriched TRANSFAC motifs involved in a biological
function
TRANSFAC GO term GO description P-value
MZF1 GO:0007275 Multicellular
organismal development
0.03
bHLH GO:0007275 Multicellular organismal
development
0.04
bHLH GO:0019219 Regulation of nucleobase, nucleoside,
nucleotide and nucleic acid
metabolic process
0.04
CP2 GO:0007267 Cell–cell signaling 0.04
AP1 GO:0007275 Multicellular organismal
development
0.05
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Figure 7. p63 and p73 binding to p53 targets. (A) Overlap of p53-
binding sites also bound by p63 and p73 in Saos2 inducible cell lines as
determined by ChIP-on-chip on the dedicated p53 array. (B) p53 motif
identiﬁed with p53scan, visualized using WebLogo for p53-binding sites
also bound by p63 or p73 (upper panel) and binding sites only bound
by p53 (lower panel).
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We have developed a new algorithm, p53scan, which
incorporates the motif derived de novo from the genome-
wide binding sites identiﬁed in this study as shown in
Figure 4A. Although this motif resembles the diﬀerent
versions of the p53-binding motif described up to now, it
more accurately reﬂects the in vivo binding preference of
p53, as this new motif is based on information from
hundreds of binding sites. Indeed, comparisons of p53scan
to other publicly available algorithms, including p53MH,
which has been most widely used, show that it produces
markedly better results in the metrics that were tested in
this study. In addition, we compared p53scan to the algo-
rithm developed by Wei et al. (37), called p53PET model,
with the sequences identiﬁed in their study as input. We
found more sequences containing a motif with p53scan
than with p53PET model (82% versus 72%) at the same
speciﬁcity level. This conﬁrms that the sensitivity of
p53scan is not limited to the binding sites of our ChIP-
on-chip dataset, but that it can also be used for future
analysis of other binding data. As a publicly accessible,
intuitive and above all sensitive and speciﬁc algorithm,
p53scan is a useful addition to the available tools that will
help characterize the widely diverse binding preference
of p53.
When analyzing our p53-binding sites with p53scan,
83% of the identiﬁed binding sites contained a motif that
is reminiscent of the p53-binding motif. The predominant
motif has no spacer in between the two half-sites, although
there is a small fraction with a spacer of one nucleotide.
This is in agreement with the genome-wide spacer
distribution found previously (37). In the most highly
enriched group of target sites, nearly all bound sequences
contain our p53-consensus motif. This suggests that
almost all highly enriched p53-binding sites are bound in
a direct sequence-speciﬁc manner dependent on the
consensus motif. Of all the identiﬁed binding sites, in
17% p53scan cannot detect the p53 consensus motif.
Although previous studies have also found p53-binding
sites without a detectable p53-consensus motif (36,37), we
ﬁnd less of those binding sites in our study using the more
inclusive identiﬁcation of the motif by p53scan. The fact
that no p53 motif can be identiﬁed in a small subset of
binding sites can have several reasons: either p53 is also
able to bind purely on the basis of DNA topology
independent of the sequence (11), or it might bind to a
diﬀerent motif like microsatellites for the PIG3 target gene
(9). The remaining sites without a common motif could of
course also be bound due to indirect binding of p53 to
chromatin.
By grouping the binding sites according to their ChIP/
Total ratio, we found a positive correlation with both the
percentage of binding sites containing a p53-binding
motif, as well as the degree of similarity of the identiﬁed
motifs with the p53 consensus motif. Thus, the more the
binding sequence resembled the p53 consensus motif,
the higher the ChIP/Total ratio. This is in accordance with
the structural data of DNA-bound p53 that showed that
protein–DNA interfaces vary as a function of the speciﬁc
base sequence of the DNA (74). From this structural data,
it was also concluded that the diﬀerential binding aﬃnity
is correlated with sequence-speciﬁc variations, which have
a direct inﬂuence on the protein-DNA contact geometry.
The binding of p53 to DNA occurs in the context of
other transcription factors and cofactors. It has been
shown for individual target genes that other transcrip-
tional activators or repressors can act together with p53
and can have diﬀerential eﬀects on the transcription of
target genes. Therefore, we analyzed common cis-elements
among the genome-wide set of p53-binding sites. We ﬁnd
potential SP1-binding sequences to be highly enriched in
the vicinity of p53-binding sites in our global approach;
p53 has been reported to require the cooperation of Sp1 or
a Sp1-like factor for transcriptional activation of the
human BAX and p21 promoter (69,75). For bHLH
motifs, which we found to be enriched in our set of
target sites, it is known that the p53 promoter itself
contains a functional consensus sequence for bHLH
proteins. In the murine p53 promoter, this element has
been shown to be required for full promoter activity (20).
The fact that we ﬁnd bHLH motifs enriched in the vicinity
of p53-binding sites, shows that these factors might be
involved in a positive feedforward regulation of p53
pathways. Thus, our ﬁndings extend the analysis of the
transcriptional environment of single targets to a larger
subset of target genes derived from a global screen. In the
future, we will need to elucidate what biological con-
sequences might result from certain combinatorial inter-
play between p53 and other cobinding factors. Therefore,
an interesting challenge will lie in the elucidation of which
transcription factor complexes can be found at which p53-
target genes and whether certain biological responses
appear to be dependent on the macro-molecular tran-
scription factor complexes at p53-binding sites. A ﬁrst
interesting approach to purify macromolecular complexes
at diﬀerent subsets of p53-target genes was done by
Tanaka et al. (22) by fractionating cross-linked p53-
associated chromatin and identifying the human cellular
apoptosis susceptibility protein (hCAS/CSE1L) in the one
fraction of a subset of p53 target promoters, including
PIG3, in a p53-autonomous manner. Thus, it remains to
be seen whether also for other cellular response pathways
speciﬁc combinations of cobinding factors can be isolated
at p53-target genes.
Global binding ofp73 and p63to p53-binding sites
For the ﬁrst time, we investigated on a global scale to
which extent p53-binding sites can be occupied by p73 and
p63 upon a speciﬁc stress signal in vivo. We found that
72% of the p53-binding sites can also be bound by p73
and/or p63. Some groups have postulated diﬀerences in
binding motif for the p53 family members, but this is
mostly based on individual targets or in vitro derived data.
Lokshin et al. (72) showed the importance of ﬁve bases in
the p53 consensus sequence for stable binding of in vitro
p73 to DNA. In our global binding site set, we cannot
diﬀerentiate between the sets of shared and p53-only
binding sites on the basis of this sequence diﬀerence. The
fraction of motifs containing these ﬁve bases was
comparable in both sets. We could also not identify a
Nucleic Acids Research, 2008, Vol. 36, No. 11 3651signiﬁcant diﬀerence between the motif for p53 in shared
binding sides or sites exclusively bound by p53. The fact
that we did not ﬁnd speciﬁc motif variation, is in
agreement with the genome-wide screen for p63-binding
sites by Yang et al. (62) and in vitro studies from Perez
et al. (76), which showed with a SELEX approach that
p63 binds principally to the p53-consensus motif, prefer-
entially to a slightly more degenerate form of it. Therefore,
we conclude that p63 and p73 can bind to p53-binding
sites on a large scale, which may imply that the stress
response is mediated in part by either competitive or
cooperative binding of p53 family members to target
genes. Alternatively, this could hint at the possibility that
p63 and p73 are capable of taking over part of the
function of p53 if needed.
This study provides a global set of high-conﬁdence
p53-binding sites, which greatly expands the known,
experimentally validated p53 binding repertoire and
gives a global insight into their characteristics. These
data can serve as a valuable knowledgebase for further
research, in which new functional studies will help to
further clarify the complex role of p53 and its family
members.
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